​

4D Molecular Therapeutics (FDMT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

FDMT Stock Forecast

4D Molecular Therapeutics stock forecast is as follows: an average price target of $38.33 (represents a 507.45% upside from FDMT’s last price of $6.31) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

FDMT Price Target

The average price target for 4D Molecular Therapeutics (FDMT) is $38.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $36.00. This represents a potential 507.45% upside from FDMT's last price of $6.31.

FDMT Analyst Ratings

Buy

According to 7 Wall Street analysts, 4D Molecular Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FDMT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

4D Molecular Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 19, 2024Kostas BiliourisBMO Capital$40.00$13.28201.20%533.91%
Sep 19, 2024Geulah LivshitsLoop Capital Markets$39.00$13.31192.99%518.07%
Sep 19, 2024Matthew CaufieldH.C. Wainwright$36.00$13.31170.44%470.52%
Apr 15, 2024Lisa WalterRBC Capital$40.00$26.3551.80%533.91%
Apr 15, 2024Gena WangBarclays$45.00$26.3570.78%613.15%
Apr 01, 2024Nalin TejavibulyaJefferies$58.00$31.8682.05%819.18%
Mar 28, 2024Kostas BiliourisBMO Capital$63.00$31.5999.43%898.42%
Feb 06, 2024Kostas BiliourisBMO Capital$70.00$30.70127.98%1009.35%
Jul 05, 2023Geulah LivshitsChardan Capital$30.00$18.4362.78%375.44%
Nov 18, 2022H.C. Wainwright$36.00$22.4060.71%470.52%
Apr 05, 2022Josh SchimmerEvercore ISI$40.00$14.66172.85%533.91%

The latest 4D Molecular Therapeutics stock forecast, released on Sep 19, 2024 by Kostas Biliouris from BMO Capital, set a price target of $40.00, which represents a 201.20% increase from the stock price at the time of the forecast ($13.28), and a 533.91% increase from FDMT last price ($6.31).

4D Molecular Therapeutics Price Target by Period

1M3M12M
# Anlaysts-38
Avg Price Target-$38.33$48.88
Last Closing Price$6.31$6.31$6.31
Upside/Downside-100.00%507.45%674.64%

In the current month, the average price target of 4D Molecular Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 4D Molecular Therapeutics's last price of $6.31. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 23, 2024Cantor FitzgeraldNeutralDowngrade
Sep 19, 2024BMO CapitalOutperformOutperformHold
Sep 19, 2024Chardan CapitalBuyBuyHold
Sep 19, 2024H.C. WainwrightBuyBuyHold
Sep 09, 2024Chardan CapitalUnderperformUnderperformHold
Sep 09, 2024RBC CapitalBuyBuyHold
Jul 22, 2024RBC CapitalOutperformOutperformHold
Jul 18, 2024RBC CapitalBuyBuyHold
Jun 07, 2024JefferiesUnderperformUnderperformHold
Jun 07, 2024RBC CapitalBuyBuyHold
Jun 07, 2024BMO CapitalOutperformOutperformHold
Apr 15, 2024RBC CapitalOutperformOutperformHold
Apr 15, 2024BarclaysOverweightInitialise
Apr 01, 2024JefferiesBuyBuyHold
Mar 28, 2024BMO CapitalOutperformOutperformHold
Mar 01, 2024Goldman SachsUnderperformUnderperformHold
Mar 01, 2024RBC CapitalBuyBuyHold
Feb 07, 2024RBC CapitalBuyBuyHold
Feb 07, 2024Goldman SachsUnderperformUnderperformHold
Oct 18, 2023Leerink PartnersOutperformUpgrade
Nov 15, 2022Goldman SachsBuyUpgrade

4D Molecular Therapeutics's last stock rating was published by Cantor Fitzgerald on Sep 23, 2024. The company Downgrade its FDMT rating from "null" to "Neutral".

4D Molecular Therapeutics Financial Forecast

4D Molecular Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Revenue--------$-20.74M$20.20M$239.00K$298.00K$1.25M$500.00K$162.00K$1.22M$92.00K$1.37M$14.58M$2.00M
Avg Forecast$250.00K$166.67K$168.33K$176.00K$1.53M$1.62M$1.27M$1.45M$8.07M$848.33K$1.28M$873.40K$873.40K$856.00K$758.33K$900.00K$900.00K$587.50K$562.50K$2.60M
High Forecast$624.81K$416.54K$420.70K$439.87K$2.68M$1.63M$1.27M$1.45M$21.25M$2.12M$3.21M$2.18M$2.18M$856.00K$758.33K$900.00K$900.00K$587.50K$562.50K$3.12M
Low Forecast$454.00$302.00$305.00$319.00$19.12K$1.60M$1.27M$1.45M$345.48K$1.54K$2.33K$1.59K$1.59K$856.00K$758.33K$900.00K$900.00K$587.50K$562.50K$2.08M
# Analysts11134244544433435458
Surprise %---------2.57%23.82%0.19%0.34%1.43%0.58%0.21%1.35%0.10%2.33%25.92%0.77%

4D Molecular Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $1.45M, with a low forecast of $1.45M, and a high forecast of $1.45M. FDMT's average Quarter revenue forecast represents a -106.99% decrease compared to the company's last Quarter revenue of $-20.74M (Dec 23).

4D Molecular Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11134244544433435458
EBITDA--------$-29.80M$-12.58M$-32.14M$-30.11M$-27.33M$-25.62M$-27.59M$-25.61M$-23.20M$-21.86M$-7.22M$-16.02M
Avg Forecast$-250.00K$-166.67K$-168.33K$-176.00K$-1.53M$-1.62M$-1.27M$-1.45M$-8.07M$-848.33K$-1.28M$-873.40K$-873.40K$-856.00K$-758.33K$-25.24M$-900.00K$-587.50K$-562.50K$-20.85M
High Forecast$-454.00$-302.00$-305.00$-319.00$-19.12K$-1.60M$-1.27M$-1.45M$-345.48K$-1.54K$-2.33K$-1.59K$-1.59K$-856.00K$-758.33K$-20.19M$-900.00K$-587.50K$-562.50K$-16.68M
Low Forecast$-624.81K$-416.54K$-420.70K$-439.87K$-2.68M$-1.63M$-1.27M$-1.45M$-21.25M$-2.12M$-3.21M$-2.18M$-2.18M$-856.00K$-758.33K$-30.29M$-900.00K$-587.50K$-562.50K$-25.02M
Surprise %--------3.69%14.83%25.01%34.47%31.29%29.93%36.39%1.01%25.77%37.20%12.83%0.77%

undefined analysts predict FDMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 4D Molecular Therapeutics's previous annual EBITDA (undefined) of $NaN.

4D Molecular Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11134244544433435458
Net Income--------$-33.71M$-10.26M$-29.62M$-27.26M$-27.27M$-24.09M$-27.41M$-26.18M$-25.08M$-22.24M$-7.59M$-16.41M
Avg Forecast$-52.04M$-51.80M$-48.89M$-45.42M$-46.71M$-37.55M$-38.01M$-41.16M$-34.07M$-43.54M$-49.63M$-43.65M$-46.89M$-46.77M$-44.92M$-26.01M$-46.99M$-37.59M$-45.88M$-21.34M
High Forecast$15.49M$15.42M$14.55M$13.52M$-33.61M$11.18M$11.31M$12.25M$-19.54M$12.96M$14.77M$12.99M$13.96M$-46.77M$-44.92M$-20.81M$-46.99M$-37.59M$-45.88M$-17.07M
Low Forecast$-153.46M$-152.77M$-144.17M$-133.93M$-62.66M$-110.73M$-112.09M$-121.38M$-41.08M$-128.40M$-146.35M$-128.72M$-138.27M$-46.77M$-44.92M$-31.22M$-46.99M$-37.59M$-45.88M$-25.61M
Surprise %--------0.99%0.24%0.60%0.62%0.58%0.52%0.61%1.01%0.53%0.59%0.17%0.77%

4D Molecular Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FDMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

4D Molecular Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11134244544433435458
SG&A--------$10.60M$9.11M$8.79M$7.99M$8.47M$8.05M$8.17M$8.23M$7.33M$8.19M$6.95M$5.54M
Avg Forecast$854.32K$569.55K$575.24K$601.44K$5.23M$5.53M$4.33M$4.95M$27.57M$2.90M$4.39M$2.98M$2.98M$2.88M$2.55M$3.03M$3.03M$1.98M$1.89M$8.75M
High Forecast$2.14M$1.42M$1.44M$1.50M$9.15M$5.58M$4.33M$4.95M$72.61M$7.25M$10.97M$7.46M$7.46M$2.88M$2.55M$3.03M$3.03M$1.98M$1.89M$10.50M
Low Forecast$1.55K$1.03K$1.04K$1.09K$65.34K$5.47M$4.33M$4.95M$1.18M$5.27K$7.98K$5.42K$5.42K$2.88M$2.55M$3.03M$3.03M$1.98M$1.89M$7.00M
Surprise %--------0.38%3.14%2.00%2.68%2.84%2.80%3.20%2.72%2.42%4.15%3.68%0.63%

4D Molecular Therapeutics's average Quarter SG&A projection for Mar 24 is $4.95M, based on 4 Wall Street analysts, with a range of $4.95M to $4.95M. The forecast indicates a -53.29% fall compared to FDMT last annual SG&A of $10.60M (Dec 23).

4D Molecular Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11134244544433435458
EPS--------$-0.00$-0.24$-0.77$-0.83$-0.84$-0.74$-0.85$-0.81$-0.93$-0.82$-0.28$-0.61
Avg Forecast$-0.94$-0.93$-0.88$-0.82$-0.84$-0.68$-0.68$-0.74$-0.61$-0.78$-0.89$-0.79$-0.84$-0.85$-0.81$-0.85$-0.85$-0.68$-0.83$-1.43
High Forecast$0.28$0.28$0.26$0.24$-0.60$0.20$0.20$0.22$-0.35$0.23$0.27$0.23$0.25$-0.85$-0.81$-0.85$-0.85$-0.68$-0.83$-1.14
Low Forecast$-2.76$-2.75$-2.60$-2.41$-1.13$-1.99$-2.02$-2.18$-0.74$-2.31$-2.63$-2.32$-2.49$-0.85$-0.81$-0.85$-0.85$-0.68$-0.83$-1.72
Surprise %--------0.00%0.31%0.86%1.06%1.00%0.87%1.05%0.95%1.09%1.21%0.34%0.43%

According to undefined Wall Street analysts, 4D Molecular Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FDMT previous annual EPS of $NaN (undefined).

4D Molecular Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PASGPassage Bio$0.67$6.00795.52%Buy
BDTXBlack Diamond Therapeutics$2.50$20.00700.00%Buy
FDMT4D Molecular Therapeutics$6.32$38.33506.49%Buy
BMEABiomea Fusion$4.64$23.33402.80%Buy
CCCCC4 Therapeutics$4.05$20.00393.83%Buy
GOSSGossamer Bio$0.87$3.75331.03%Buy
IPSCCentury Therapeutics$1.17$5.00327.35%Buy
CGEMCullinan Oncology$11.49$34.00195.91%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
REPLReplimune Group$11.72$19.0062.12%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
KRONKronos Bio$0.96$1.004.17%Buy

FDMT Forecast FAQ

Is 4D Molecular Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, 4D Molecular Therapeutics (FDMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of FDMT's total ratings.

What is FDMT's price target?

4D Molecular Therapeutics (FDMT) average price target is $38.33 with a range of $36 to $40, implying a 507.45% from its last price of $6.31. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will 4D Molecular Therapeutics stock go up soon?

According to Wall Street analysts' prediction for FDMT stock, the company can go up by 507.45% (from the last price of $6.31 to the average price target of $38.33), up by 533.91% based on the highest stock price target, and up by 470.52% based on the lowest stock price target.

Can 4D Molecular Therapeutics stock reach $9?

FDMT's average twelve months analyst stock price target of $38.33 supports the claim that 4D Molecular Therapeutics can reach $9 in the near future.

What are 4D Molecular Therapeutics's analysts' financial forecasts?

4D Molecular Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5.86M (high $7.03M, low $4.33M), average EBITDA is $-5.862M (high $-4.335M, low $-7.026M), average net income is $-163M (high $1.13M, low $-407M), average SG&A $20.03M (high $24.01M, low $14.81M), and average EPS is $-2.942 (high $0.0203, low $-7.324). FDMT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $761K (high $1.9M, low $1.38K), average EBITDA is $-761K (high $-1.38K, low $-1.902M), average net income is $-198M (high $58.98M, low $-584M), average SG&A $2.6M (high $6.5M, low $4.72K), and average EPS is $-3.567 (high $1.06, low $-10.518).

Did the FDMT's actual financial results beat the analysts' financial forecasts?

Based on 4D Molecular Therapeutics's last annual report (Dec 2022), the company's revenue was $3.13M, which missed the average analysts forecast of $3.39M by -7.64%. Apple's EBITDA was $-110M, beating the average prediction of $-27.728M by 296.82%. The company's net income was $-101M, missing the average estimation of $-165M by -38.59%. Apple's SG&A was $32.91M, beating the average forecast of $11.44M by 187.72%. Lastly, the company's EPS was $-3.12, missing the average prediction of $-3.353 by -6.94%. In terms of the last quarterly report (Dec 2023), 4D Molecular Therapeutics's revenue was $-20.741M, missing the average analysts' forecast of $8.07M by -357.11%. The company's EBITDA was $-29.803M, beating the average prediction of $-8.067M by 269.45%. 4D Molecular Therapeutics's net income was $-33.707M, missing the average estimation of $-34.069M by -1.06%. The company's SG&A was $10.6M, missing the average forecast of $27.57M by -61.55%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-0.613 by -99.85%